The Drug Resistance and Sensitivity Network (DRSN) is a consortium to conduct collaborative research focused on innovative strategies to understand and combat mechanisms of tumor resistance (intrinsic or acquired) and/or to exploit tumor sensitivity to anti-cancer therapies. The DRSN is a critical preclinical component to NCI’s clinical drug development and its research has clear translational potential to inspire and aid the development of novel therapeutic strategies in clinical settings.
      The DRSN is supported by NIH Cancer MoonshotSM. The Cancer MoonshotSM aims to accelerate cancer research to make more therapies available to more patients, while also improving our ability to prevent cancer and detect it at an early stage.